172@29@17@247!~!172@29@0@53!~!|news|tags|granules-india.html!~!|controller|tag.php
granules india
Jump to
342 Results Found
  • Buy Granules India; target of Rs 330: Anand Rathi Jul 21, 2020 06:05 PM IST

    Buy Granules India; target of Rs 330: Anand Rathi

    Anand Rathi recommended hold rating on Granules India with a target price of Rs 330 in its research report dated July 20, 2020.

  • Buy Granules India; target of Rs 327: Geojit Jul 21, 2020 01:55 PM IST

    Buy Granules India; target of Rs 327: Geojit

    Geojit recommended is bullish on Granules India recommended buy rating on the stock with a target price of Rs 327 in its research report dated July 20, 2020.

  • Buy Granules India; target of Rs 340: Emkay Global Financial Jul 21, 2020 01:43 PM IST

    Buy Granules India; target of Rs 340: Emkay Global Financial

    Emkay Global Financial is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 340 in its research report dated July 17, 2020.

  • Buy Granules India ; target of Rs 315: Motilal Oswal Jul 20, 2020 12:14 PM IST

    Buy Granules India ; target of Rs 315: Motilal Oswal

    Motilal Oswal is bullish on Granules India recommended buy rating on the stock with a target price of Rs 765 in its research report dated July 18, 2020.

  • Granules India Standalone June 2020 Net Sales at Rs 742.92 crore, up 30.83% Y-o-Y Jul 20, 2020 09:25 AM IST

    Granules India Standalone June 2020 Net Sales at Rs 742.92 crore, up 30.83% Y-o-Y

  • Granules India Q1 net profit rises 34% to Rs 111.4 crore Jul 17, 2020 04:00 PM IST

    Granules India Q1 net profit rises 34% to Rs 111.4 crore

    The company had posted a net profit of Rs 83.24 crore for the corresponding period of the previous financial year, Granules India said in a filing to the BSE.

  • Granules India shares hit new high after Q1 profit jumps 34% Jul 17, 2020 12:48 PM IST

    Granules India shares hit new high after Q1 profit jumps 34%

    The company's consolidated net profit rose 34 percent to Rs 111.4 crore against Rs 83.2 crore YoY. Its consolidated revenue went up 23.6 percent at Rs 735.6 crore against Rs 595.3 crore YoY.

  • Buy Granules India; target of Rs 227: Anand Rathi Jun 05, 2020 09:34 AM IST

    Buy Granules India; target of Rs 227: Anand Rathi

    Anand Rathi is bullish on Granules India has recommended buy rating on the stock with a target price of Rs 227 in its research report dated June 03, 2020.

  • Granules India Standalone March 2020 Net Sales at Rs 486.87 crore, down 13.21% Y-o-Y Jun 03, 2020 09:50 AM IST

    Granules India Standalone March 2020 Net Sales at Rs 486.87 crore, down 13.21% Y-o-Y

  • Granules India Consolidated March 2020 Net Sales at Rs 599.88 crore, down 2.19% Y-o-Y Jun 03, 2020 09:07 AM IST

    Granules India Consolidated March 2020 Net Sales at Rs 599.88 crore, down 2.19% Y-o-Y

  • JB Chemicals, Granules share price up 2-4% on USFDA approval Apr 27, 2020 12:30 PM IST

    JB Chemicals, Granules share price up 2-4% on USFDA approval

    Granules has a total of 27 ANDA approvals from US FDA (25 Final approvals and 2 tentative approvals).

  • Granules India share price rises 6% on USFDA nod Apr 24, 2020 10:05 AM IST

    Granules India share price rises 6% on USFDA nod

    Granules now has a total of 26 ANDA approvals from US FDA (24 Final approvals and 2 tentative approvals).

  • Granules India gets USFDA approval for Butalbital, Acetaminophen, Caffeine capsules Apr 09, 2020 02:00 PM IST

    Granules India gets USFDA approval for Butalbital, Acetaminophen, Caffeine capsules

    Granules India Ltd on Thursday said its foreign subsidiary has received approval from the US health regulator for Butalbital, Acetaminophen and Caffeine Capsules used to treat tension headaches.

  • Granules India share price gains 12% on EU GMP approval Apr 07, 2020 03:38 PM IST

    Granules India share price gains 12% on EU GMP approval

    The EU nod for the company's Visakhapatnam facility will be valid for three years.

  • COVID-19 | Supply chain disruptions: The challenges ahead for India Inc Apr 01, 2020 08:28 AM IST

    COVID-19 | Supply chain disruptions: The challenges ahead for India Inc

  • Granules India share price gains 7% on buyback approval Mar 11, 2020 11:05 AM IST

    Granules India share price gains 7% on buyback approval

    The buyback committee has approved March 20, 2020 as the record date.

  • Granules India share price gains 4% on USFDA nod Mar 05, 2020 12:51 PM IST

    Granules India share price gains 4% on USFDA nod

    The company now have a total of 24 ANDA approvals from US FDA (22 Final approvals and 2 tentative approvals).

  • Granules India gets tentative nod from USFDA for expectorant tablets Feb 13, 2020 12:27 PM IST

    Granules India gets tentative nod from USFDA for expectorant tablets

    "US Food & Drug Administration (USFDA) has tentatively approved its Abbreviated New Drug Application for Guaifenesin extended-release tablets, 600 mg and 1200 mg (OTC)," the company said in a filing to the BSE.

  • Granules India gets tentative nod from USFDA for generic Colchicine capsules Feb 11, 2020 03:37 PM IST

    Granules India gets tentative nod from USFDA for generic Colchicine capsules

    The US Food and Drug Administration (USFDA) has tentatively approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals Inc for Colchicine capsules in the strength of 0.6 mg, Granules India said in a filing to the BSE.

  • Granules Pharmaceuticals, Inc gets USFDA nod for Colchicine tablets Feb 06, 2020 10:47 AM IST

    Granules Pharmaceuticals, Inc gets USFDA nod for Colchicine tablets

    Familial mediterranean fever is a genetic disorder that causes recurrent episodes of fever that are typically accompanied by pain in the abdomen, chest, or joints.

  • Granules India hits 52-week high after USFDA approval Feb 06, 2020 10:02 AM IST

    Granules India hits 52-week high after USFDA approval

    Colchicine tablets are used in the treatment of Familial Mediterranean Fever.

  • Granules India share price jumps 5% on USFDA nod for antiviral medicine Feb 05, 2020 10:56 AM IST

    Granules India share price jumps 5% on USFDA nod for antiviral medicine

    Domestic brokerage firm Sharekhan by BNP Paribas has maintained a positive view on the stock with an upside potential of 12-15 percent while Anand Rathi Share has a buy recommendation with a target price of Rs 181.

  • Granules India arm gets USFDA nod for Valganciclovir hydrochloride oral solution Feb 05, 2020 10:35 AM IST

    Granules India arm gets USFDA nod for Valganciclovir hydrochloride oral solution

    "The US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc, a-wholly owned foreign subsidiary of Granules India Ltd for Valganciclovir hydrochloride for oral solution, 50 mg/ml," the company said in a regulatory filing.

  • Granules India divests entire stake in Granules-Biocause Pharmaceutical Feb 04, 2020 11:35 AM IST

    Granules India divests entire stake in Granules-Biocause Pharmaceutical

    Last year, Granules India had intimated about the divestment of the entire stake of the JV company for a total consideration of RMB 109 million (around Rs 110.8 crore).

  • Granules India hit fresh 52-week high; brokerages positive on growth prospects Jan 23, 2020 12:19 PM IST

    Granules India hit fresh 52-week high; brokerages positive on growth prospects

    Domestic brokerage firm Sharekhan by BNP Paribas has maintained a positive view on the stock with an upside potential of 12-15 percent.

Sections